| [1] |
Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing)[J]. J Clin Hepatol, 2017, 33(9): 1627-1637. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2017.09.003 |
| [2] |
MOHTY M, MALARD F, ABECASSIS M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: A new classification from the European Society for Blood and Marrow Transplantation[J]. Bone Marrow Transplant, 2016, 51(7): 906-912. DOI: 10.1038/bmt.2016.130 |
| [3] |
WELDEAREGAY KT, GEBREKIDAN MG, GEZAHEGNE AA. Health impact of hepatic-venous-occlusive disease in a small town in Ethiopia-Case study from Tahtay koraro district in Tigray region, 2017[J]. PLoS One, 2019, 14(11): e0224659. DOI: 10.1371/journal.pone.0224659 |
| [4] |
PENG C, ZHANG X, ZHANG F, et al. Clinical efficacy and safety of anticoagulation therapy for Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: A retrospective multicenter cohort study[J]. Eur J Gastroenterol Hepatol, 2020, 32(9): 1168-1178. DOI: 10.1097/MEG.0000000000001630 |
| [5] |
ZHUGE Y, LIU Y, XIE W, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. J Gastroenterol Hepatol, 2019, 34(4): 634-642. DOI: 10.1111/jgh.14612 |
| [6] |
OPLATOWSKA M, ELLIOTT CT, HUET AC, et al. Development and validation of a rapid multiplex ELISA for pyrrolizidine alkaloids and their N-oxides in honey and feed[J]. Anal Bioanal Chem, 2014, 406(3): 757-770. DOI: 10.1007/s00216-013-7488-7 |
| [7] |
YANG XQ, YE J, LI X, et al. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes[J]. World J Gastroenterol, 2019, 25(28): 3753-3763. DOI: 10.3748/wjg.v25.i28.3753 |
| [8] |
RUAN J, YANG M, FU P, et al. Metabolic activation of pyrrolizidine alkaloids: Insights into the structural and enzymatic basis[J]. Chem Res Toxicol, 2014, 27(6): 1030-1039. DOI: 10.1021/tx500071q |
| [9] |
RUAN J, GAO H, LI N, et al. Blood pyrrole-protein adducts—a biomarker of pyrrolizidine alkaloid-induced liver injury in humans[J]. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev, 2015, 33(4): 404-421. DOI: 10.1080/10590501.2015.1096882 |
| [10] |
MA J, XIA Q, FU PP, et al. Pyrrole-protein adducts-A biomarker of pyrrolizidine alkaloid-induced hepatotoxicity[J]. J Food Drug Anal, 2018, 26(3): 965-972. DOI: 10.1016/j.jfda.2018.05.005 |
| [11] |
EBMEYER J, BEHREND J, LORENZ M, et al. Pyrrolizidine alkaloid-induced alterations of prostanoid synthesis in human endothelial cells[J]. Chem-Biol Interact, 2019, 298: 104-111. DOI: 10.1016/j.cbi.2018.11.007 |
| [12] |
HARB R, XIE G, LUTZKO C, et al. Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury[J]. Gastroenterology, 2009, 137(2): 704-712. DOI: 10.1053/j.gastro.2009.05.009 |
| [13] |
LI YH, TAI WC, XUE JY, et al. Proteomic study of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome in rats[J]. Chem Res Toxicol, 2015, 28(9): 1715-1727. DOI: 10.1021/acs.chemrestox.5b00113 |
| [14] |
NAKAMURA K, HATANO E, NARITA M, et al. Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9[J]. J Hepatol, 2012, 57(5): 1037-1043. DOI: 10.1016/j.jhep.2012.07.004 |
| [15] |
HUANG Z, CHEN M, WEI M, et al. Liver inflammatory injury initiated by DAMPs-TLR4-MyD88/TRIF-NFκB signaling pathway is involved in monocrotaline-induced HSOS[J]. Toxicol Sci, 2019, 172(2): 385-397. DOI: 10.1093/toxsci/kfz193 |
| [16] |
ITO Y. A novel therapeutic strategy for liver sinusoidal obstruction syndrome[J]. J Gastroenterol Hepatol, 2009, 24(6): 933-934. DOI: 10.1111/j.1440-1746.2009.05839.x |
| [17] |
DELEVE LD, WANG X, TSAI J, et al. Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition[J]. Gastroenterology, 2003, 125(3): 882-890. DOI: 10.1016/S0016-5085(03)01056-4 |
| [18] |
EZZAT T, VAN DEN BROEK MAJ, DAVIES N, et al. The flavonoid monoHER prevents monocrotaline-induced hepatic sinusoidal injury in rats[J]. J Surg Oncol, 2012, 106(1): 72-78. DOI: 10.1002/jso.23046 |
| [19] |
OKUNO M, HATANO E, NAKAMURA K, et al. Regorafenib suppresses sinusoidal obstruction syndrome in rats[J]. J Surg Res, 2015, 193(2): 693-703. DOI: 10.1016/j.jss.2014.08.052 |
| [20] |
HSIA DA, MITRA SK, HAUCK CR, et al. Differential regulation of cell motility and invasion by FAK[J]. J Cell Biol, 2003, 160(5): 753-767. DOI: 10.1083/jcb.200212114 |
| [21] |
HIBATA K, KIKKAWA F, NAWA A, et al. Bothfocal adhesion kinase and c-Ras are required for the enhanced matrixmetalloproteinase 9 secretion by fibronectin in ovarian cancer cells[J]. CancerRes, 1998, 58: 900-903.
|
| [22] |
MIN L, HE B, HUI L. Mitogen-activated protein kinases in hepatocellular carcinoma development[J]. Semin Cancer Biol, 2011, 21(1): 10-20. DOI: 10.1016/j.semcancer.2010.10.011 |
| [23] |
CHOJKIER M. Hepatic sinusoidal-obstruction syndrome: Toxicity of pyrrolizidine alkaloids[J]. J Hepatol, 2003, 39(3): 437-446. DOI: 10.1016/S0168-8278(03)00231-9 |
| [24] |
YANG M, RUAN J, FU PP, et al. Cytotoxicity of pyrrolizidine alkaloid in human hepatic parenchymal and sinusoidal endothelial cells: Firm evidence for the reactive metabolites mediated pyrrolizidine alkaloid-induced hepatotoxicity[J]. Chem-Biol Interact, 2016, 243: 119-126. DOI: 10.1016/j.cbi.2015.09.011 |
| [25] |
DUSEMUND B, NOWAK N, SOMMERFELD C, et al. Risk assessment of pyrrolizidine alkaloids in food of plant and animal origin[J]. Food Chem Toxicol, 2018, 115: 63-72. DOI: 10.1016/j.fct.2018.03.005 |
| [26] |
WANG X, KANEL GC, DELEVE LD. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat[J]. Hepatology, 2000, 31(2): 428-434. DOI: 10.1002/hep.510310224 |
| [27] |
CONOTTE R, COLET JM. A metabonomic evaluation of the monocrotaline-induced sinusoidal obstruction syndrome (SOS) in rats[J]. Toxicol Appl Pharmacol, 2014, 276(2): 147-156. DOI: 10.1016/j.taap.2014.02.008 |
| [28] |
HESSEL-PRAS S, BRAEUNING A, GUENTHER G, et al. The pyrrolizidine alkaloid senecionine induces CYP-dependent destruction of sinusoidal endothelial cells and cholestasis in mice[J]. Arch Toxicol, 2020, 94(1): 219-229. DOI: 10.1007/s00204-019-02582-8 |
| [29] |
YANG M, RUAN J, GAO H, et al. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans[J]. Arch Toxicol, 2017, 91(12): 3913-3925. DOI: 10.1007/s00204-017-2013-y |
| [30] |
NARITA M, HATANO E, TAMAKI N, et al. Dai-kenchu-to attenuates rat sinusoidal obstruction syndrome by inhibiting the accumulation of neutrophils in the liver[J]. J Gastroenterol Hepatol, 2009, 24(6): 1051-1057. DOI: 10.1111/j.1440-1746.2009.05795.x |
| [31] |
ZHANG J, SHENG Y, SHI L, et al. Quercetin and baicalein suppress monocrotaline-induced hepatic sinusoidal obstruction syndrome in rats[J]. Eur J Pharmacol, 2017, 795: 160-168. DOI: 10.1016/j.ejphar.2016.12.015 |
| [32] |
ZHENG Z, SHI L, SHENG Y, et al. Chlorogenic acid suppresses monocrotaline-induced sinusoidal obstruction syndrome: The potential contribution of NFκB, Egr1, Nrf2, MAPKs and PI3K signals[J]. Environ Toxicol Pharmacol, 2016, 46: 80-89. DOI: 10.1016/j.etap.2016.07.002 |
| [33] |
VALLA DC, CAZALS-HATEM D. Sinusoidal obstruction syndrome[J]. Clin Res Hepatol Gastroenterol, 2016, 40(4): 378-385. DOI: 10.1016/j.clinre.2016.01.006 |
| [34] |
|
| [35] |
DELEVE LD, WANG X, GUO Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence[J]. Hepatology, 2008, 48(3): 920-930. DOI: 10.1002/hep.22351 |
| [36] |
GVNTHER S, PERROS F, RAUTOU PE, et al. Understanding the similarities and differences between hepatic and pulmonary veno-occlusive disease[J]. Am J Pathol, 2019, 189(6): 1159-1175. DOI: 10.1016/j.ajpath.2019.02.007 |
| [37] |
HIRATA M, TAJIMA H, MIYASHITA T, et al. Extravasated platelet aggregation in the livers of rats with drug-induced hepatic sinusoidal obstruction syndrome[J]. Mol Med Rep, 2017, 15(5): 3147-3152. DOI: 10.3892/mmr.2017.6407 |
| [38] |
NARMADA BC, CHIA SM, TUCKER-KELLOGG L, et al. HGF regulates the activation of TGF-β1 in rat hepatocytes and hepatic stellate cells[J]. J Cell Physiol, 2013, 228(2): 393-401. DOI: 10.1002/jcp.24143 |
| [39] |
GRESSNER AM, WEISKIRCHEN R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets[J]. J Cell Mol Med, 2006, 10(1): 76-99. DOI: 10.1111/j.1582-4934.2006.tb00292.x |
| [40] |
ZHU H, CHU Y, HUO J, et al. Effect of prednisone on transforming growth factor-β1, connective tissue growth factor, nuclear factor-κBp65 and tumor necrosis factor-α expression in a murine model of hepatic sinusoidal obstruction syndrome induced by Gynura segetum[J]. Hepatol Res, 2011, 41(8): 795-803. DOI: 10.1111/j.1872-034X.2011.00830.x |
| [41] |
SUN K, WANG Q, HUANG XH. PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression[J]. Acta Pharmacol Sin, 2006, 27(6): 715-723. DOI: 10.1111/j.1745-7254.2006.00299.x |
DownLoad: